This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

NCT03156114 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Ezabenlimab
DRUG: BI 754111

Sponsor

Boehringer Ingelheim